UroGen Pharma's Chief Medical Officer Mark Schoenberg sold 10,000 shares worth $400,000 on July 9, 2026, under a pre-established Rule 10b5-1 trading plan adopted in August 2025. Despite the sale, Schoenberg retains 119,763 shares valued at $4.82 million. The transaction should not be viewed negatively as it was scheduled long in advance and the CMO maintains significant holdings. UroGen's Zusduri bladder cancer therapy is performing well with Q1 revenue jumping 152% to $51 million, and the company recently received FDA clearance for an investigational new drug application for UGN-501.

UroGen Pharma's Chief Medical Officer Mark Schoenberg sold 5,222 shares for approximately $143,000 on June 8, 2026, reducing his holdings by 3.60%. While his remaining stake of 139,763 shares keeps his interests aligned with investors, the sale follows a pattern of regular dispositions over the past year. The company faces headwinds from an upcoming generic competition agreement with Teva Pharmaceuticals for its flagship drug Jelmyto starting September 2030, though growth in other products like Zusduri may offset losses.

A national survey of over 1,100 bladder cancer patients conducted by the Bladder Cancer Advocacy Network (BCAN) reveals that nearly 80% of patients report fear of recurrence, with rates exceeding 90% among those under 50. The report documents significant procedural burden, with many patients undergoing five or more cystoscopies. UroGen Pharma commended the findings, emphasizing the need for treatment approaches that consider long-term quality of life alongside tumor control.

A comprehensive survey of over 1,100 bladder cancer patients reveals significant gaps in care despite advances in treatment. Key findings include diagnostic delays for women (45% initially misdiagnosed with UTIs), inadequate mental health support (41% never offered resources), and financial barriers affecting treatment decisions, particularly for younger patients.

Wildcat Capital Management, the family office of late billionaire David Bonderman, completely exited its position in UroGen Pharma by selling 495,606 shares worth $6.79 million in Q3. Despite UroGen's impressive 113% one-year rally, the exit signals disciplined profit-taking rather than loss of confidence, as biotech winners often see valuation risk increase after strong rallies.

UroGen Pharma granted restricted stock units to 14 new employees to support commercialization of Jelmyto and ZUSDURI, with up to 32,500 ordinary shares issuable upon vesting over three years.

UroGen Pharma will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, in a fireside chat format, discussing their innovative cancer treatment technologies.

UroGen Pharma published a comprehensive review highlighting the clinical efficacy of ZUSDURI, an FDA-approved treatment for recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer, demonstrating high complete response rates and a manageable safety profile.

A class action lawsuit has been filed against UroGen Pharma regarding its UGN-102 drug application, alleging misleading statements about clinical study design and FDA approval risks. The stock price dropped significantly after FDA advisory committee voted against drug approval.

A class action lawsuit has been filed against UroGen Pharma regarding its UGN-102 drug application, alleging misleading statements about clinical study design and FDA approval risks.

A class action lawsuit has been filed against UroGen Pharma regarding its UGN-102 drug application, alleging misleading statements about clinical study design and FDA approval risks.

Law firm Bragar Eagel & Squire, P.C. has filed class action lawsuits against Organon, UroGen, Red Cat, and Fortrea, alleging misleading statements and financial misrepresentations that negatively impacted investor interests.